Elahere

ImmunoGen announced on November 14th, 2022 that the US Food and Drug Administration (FDA) had accelerated the approval of Elahere (mirvetuximab soravtansine-gynx) for the treatment of adult patients with folate receptor α(frα) positive and platinum-resistant epithelial ovarian cancer, tubal cancer or primary peritoneal cancer, who had previously received one to three systemic treatment schemes.

Box warning: eye toxicity

1.Elahere can cause serious ocular toxicity, including visual impairment, keratopathy, dry eye, photophobia, eye pain and uveitis.

2. Before starting Elahere, every other cycle in the first 8 cycles, eye examination was conducted according to clinical indications, including vision and slit lamp examination.

3. Use preventive artificial tears and topical steroids

. 4. Stop taking medicine due to eye toxicity until the symptoms improve, and then continue taking medicine at the same or reduced dose.

5. For grade 4 eye toxicity, stop using Elahere.

Elahere is used by special people.

Step 1 breastfeed

Women are advised not to breastfeed during Elahere treatment and for at least one month after the last administration.

2. Pediatric use

The safety and effectiveness of Elahere in pediatric patients have not been determined.

Adverse reactions of Elahere

The most common (≥20%) adverse reactions (including laboratory abnormalities) include visual impairment, fatigue, elevated aspartate aminotransferase, nausea, elevated alanine aminotransferase, keratopathy, abdominal pain, lymphopenia, peripheral neuropathy, diarrhea, albumin decrease, constipation, elevated alkaline phosphatase, dry eye, magnesium decrease, leukopenia, neutropenia and hemoglobin decrease.

Note: If there is any new packaging for drugs, the new packaging shall prevail. The above information comes from the Internet or translated by student volunteers in medical colleges and universities (if there are any mistakes or omissions, please help me to correct them). It is for internal discussion of medical staff only, without any basis for medication. Please consult the attending physician for specific medication guidelines.